What does HLN stock do?
The stock ticker symbol HLN represents Haleon plc, which is a major British multinational consumer healthcare enterprise publicly traded on the London Stock Exchange and the New York Stock Exchange. Purchasing HLN stock allows equity investors to participate in the financial performance, global retail sales, and dividend distributions of a corporation that produces world-renowned over-the-counter medicines, oral care products, and wellness brands like Sensodyne, Advil, and Panadol. Stock price movements are driven by quarterly retail revenue reports, consumer healthcare demand, and macroeconomic market trends.
Related FAQs
Haleon, the massive multinational consumer healthcare company specializing in over-the-counter medicines, oral care, and wellness products, was previously operated as the consumer healthcare joint venture division of GlaxoSmithKline, formed in combin...
Haleon operates as an entirely independent, standalone public corporation following its strategic corporate demerger and spin-off from GSK plc, which successfully separated its consumer healthcare division into a separate publicly traded entity.
Haleon is a global consumer health powerhouse that owns a portfolio of iconic household brands.
First Horizon Corporation (FHN) is a prominent regional banking institution providing financial services primarily across the Southeastern United States through its banking subsidiary, First Horizon Bank.
The prominent American cable news and television network known as HLN operated under the original brand name Headline News when it was launched by media mogul Ted Turner in 1982 as a sister channel to CNN.
Haleon PLC is frequently viewed by healthcare sector analysts as a stable defensive investment, supported by its massive portfolio of world-renowned consumer health and over-the-counter wellness brands.
Haleon plc, a leading global consumer healthcare multinational enterprise that produces well-known everyday health brands such as Sensodyne, Advil, and Panadol, has its global corporate headquarters located in Weybridge, Surrey, United Kingdom.
Haleon plc is frequently evaluated by consumer healthcare analysts as a stable long-term holding, supported by a world-class portfolio of market-leading over-the-counter brands, global distribution scale, and consistent defensive cash flows.
Pfizer utilizes Veeva Systems' cloud-based software solutions, commercial cloud platforms, and clinical data management applications extensively across its global pharmaceutical operations.
As of July 31, 2026, market forecasts for Haleon plc (HLN) suggest the stock price could reach $11.08 by the end of 2026, representing an approximate 9.7% increase from current rates. Long-term projections indicate a potential price of $15.
Haleon plc officially completed its high-profile spin-off from parent conglomerates GlaxoSmithKline and Pfizer, commencing independent trading on the London Stock Exchange under the ticker symbol HLN on July 18, 2022.